ghk-cu subq subcutaneous injection study human injectable dosage ghk-cu typical dose subcutaneous Frontiers The Human Tripeptide GHK-Cu in – ghk-cu peptide typical dosage subcutaneous – FDA scientists flag concerns with

More Peptides 5-Amino-1MQ (10mg) BPC-157 BPC-157, TB-500, GHK-Cu (Glow Blend) 60mg CJC-1295 (no DAC), Ipamorelin 10mg (Blend) GHK-Cu 50mg Copper Peptide Kisspeptin-10 5mg KPV (Ac-KPV-NH2) 5mg MOTS-c NAD+ Retatrutide peptide Selank 10mg Semax TB-500 (Thymosin Beta-4) (43aa) Tesamorelin 5mg Thymosin Alpha-1 Tirzepatide peptide Properties Molecular Formula Bpc-157: CHNO Cu-GHK: CHCuNO Timbetasin: CHNO Molecular Weight Bpc-157: 1419.5 Cu-GHK: 403.92 Timbetasin: 4963 Monoisotopic Mass Bpc-157: 1418.70415882 Cu-GHK: 403.1155 Timbetasin: 4960.4863169 Polar Area Bpc-157: 573 Cu-GHK: 176 Timbetasin: 2250 Complexity Bpc-157: 3040 Cu-GHK: 6 Timbetasin: 12200 XLogP Bpc-157: -9 Timbetasin: -43.5 Heavy Atom Count Bpc-157: 100 Cu-GHK: 25 Timbetasin: 347 Hydrogen Bond Donor Count Bpc-157: 16 Cu-GHK: 6 Timbetasin: 72 Rotatable Bond Count Bpc-157: 39 Cu-GHK: 11 Timbetasin: 180 Hydrogen Bond Acceptor Count Bpc-157: 24 Cu-GHK: 7 Timbetasin: 88 Identifiers CID Bpc-157: 9941957 Cu-GHK: 378611 Timbetasin: 16132341 InChI Bpc-157: InChI=1S/C62H98N16O22/c1-31(2)25-37(55(92)74-50(32(3)4)62(99)100)71-46(81)29-65-51(88)33(5)67-53(90)38(26-48(84)85)73-54(91)39(27-49(86)87)72-52(89)34(6)68-57(94)41-15-10-21-75(41)58(95)35(13-7-8-20-63)70-45(80)30-66-56(93)40-14-9-22-76(40)60(97)43-17-12-24-78(43)61(98)42-16-11-23-77(42)59(96)36(18-19-47(82)83)69-44(79)28-64/h31-43,50H,7-30,63-64H2,1-6H3,(H,65,88)(H,66,93)(H,67,90)(H,68,94)(H,69,79)(H,70,80)(H,71,81)(H,72,89)(H,73,91)(H,74,92)(H,82,83)(H,84,85)(H,86,87)(H,99,100)/t33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,50-/m0/s1 Cu-GHK: InChI=1S/C14H24N6O4.Cu/c15-4-2-1-3-10(14(23)24)20-13(22)11(19-12(21)6-16)5-9-7-17-8-18-9;/h7-8,10-11H,1-6,15-16H2,(H,17,18)(H,19,21)(H,20,22)(H,23,24)

Choose the volume that best suits your research protocols dosing requirements

Sometimes, SIRVA lasts even longer

Lyophilized peptides degrade with temperature swings

Stacking Simulator Preview how peptide combinations would affect your domains before committing to a protocol

That translates to tens of millions of people worldwide living with a condition that is only partially understood, frequently dismissed in conventional medical settings, and for which there is currently no FDA-approved treatment